Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
DETERMINISTIC E2E COMMUNICATION WITH 6G (DETERMINISTIC6G)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Public-private partnerships
Destination: Smart Networks and Services
Action type: Research and Innovation actions
Partnership: SNS (JU-JTI)
Countries involved: France,Austria,Finland,Sweden,Germany,Italy,Hungary
Call: System Architecture (HORIZON-JU-SNS-2022, 2022)
Start date: 2023-01-01
End date: 2025-09-30
Duration (months): 33.0
Total project cost (EUR): 5840449.37
EU funding (EUR): 5484377.0
Participants: 14
Project status: SIGNED

Digitalization is transforming industries and society with the adoption of edge/cloud computing, AI and digital twins. In the future, physical processes, collaborating machines, but also novel human-system-interactions will move towards a cyber-physical continuum merging the physical world of senses, actions as well as their digital programmable representations. Fundamentally new requirements for deterministic communication with predictable performance will appear for such cyber-physical end-to-end services. Wired deterministic communication standards have already emerged including Time Sensitive Networking (TSN) and Deterministic Networking (DetNet), while 5G has specified mechanisms for interworking with those standards. However, the available support of 5G in conjunction with TSN and DetNet is not sufficient for future end-to-end time-critical applications. Driven by pivotal use cases from Industry 5.0, DETERMINISTIC6G addresses three central challenges of future deterministic end-to-end communication enabled by 6G: (1) a new architecture for 6G systems providing predictable performance and integrating it end-to-end with TSN and DetNet; (2) novel data-driven awareness of stochastically evolving network performance, with time synchronization over heterogeneous domains; and (3) leveraging novel digital twins of both 6G networks and cyber-physical systems, to anticipate situational circumstances impacting determinism of networks and safety of cyber-physical systems. DETERMINISTIC6G will also devise security-by-design for deterministic communication including the integration of edge computing and the support of OPC UA into deterministic network paths. The project targets dissemination of results towards the three essential standardization bodies in this domain: 3GPP (for 6G), IEEE802.1 (for TSN) and IETF (for DetNet). With a strong consortium driving these standards, DETERMINISTIC6G will ensure uptake of the results and insights towards global 6G standards and industry fora.

Keywords: time sensitive networking,6g,deterministic communication,time critical applications,data driven architecture
Multi-scale research on nano-twinned thermal barrier coatings with high strength and toughness (TWINCER)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-03-01
End date: 2026-02-28
Duration (months): 24.0
Total project cost (EUR): 189687.36
EU funding (EUR): 189687.36
Participants: 1
Project status: TERMINATED

Thermal barrier coatings (TBCs) have been widely used to protect the substrate of hot components against the hot and corrosive environment, which have extensive applications in power sectors, aerospace engineering and chemical industrials. They are, however, facing the paradox of conflicting competition between the strength and toughness, especially under high temperature. Aiming to develop high temperature TBCs with simultaneously improved strength and toughness, this project proposes an innovative strategy of engineering nano-twinned ceramics and examines their mechanical properties under high temperature with improved mechanistic understanding, which include: i) developing novel nano-twinned TYaO4 ceramic materials via hierarchical structures; ii) examining the mechanical properties of formed TBC materials via a unique high temperature nano-indentation system up to 2000 K; 3) establishing a multi-scale simulation framework to predict the macroscopic mechanical properties; and iv) developing a twin boundary affected hardening and crack growth model to reveal the influence of nanoscale structures. Four work programs are proposed ranging from experiments, simulations to theories to realize such an ambitious plan, intervened with a careful balanced training program, dissemination and management skill development. Properly implemented, the project shall reveal for the first time the effect of hierarchical nanoscale structures on the improved mechanical properties of TYaO4 ceramics up to 2000 K, which are much needed for the development of next generations of TBCs. The project exhibits strong interdisciplinary coupling among materials science and engineering, solid mechanics, and multiscale computation engineering. Not only bearing with significant scientific potentials, the mutual benefits from this program will booster the career of the researcher significantly and promote long term knowledge exchange and collaboration between Europe and China.

Keywords: thermal barrier coatings nano twins hardening ad toughening high temperature nano indentation multi scale method
Niuiu: A breakthrough, non-pharma, wearable medical device rapidly alleviating sleep disorders via adaptive personalized neuro-modulation, starting with Parkinson's patients (Niuiu)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2390000.0
EU funding (EUR): 2390000.0
Participants: 1
Project status: SIGNED

A substantial portion of our lives is spent sleeping, constituting about one-third of our time. Sleep disorders can have profound adverse effects on our overall health, and there exists a significant connection between sleep disorders and Parkinson's Disease (PD). The presence of sleep disorders can notably elevate the risk of developing PD and exacerbate the progression of the disease. More than 75% of PD patients experience sleep disorders, making a restful night's sleep crucial for them. However, current solutions fall short in addressing their specific needs due to the complex nature of the disease. NYX is proud to introduce Niuiu: a groundbreaking, patented, non-medication, and non-invasive solution designed to deliver highly personalized, autonomous, and adaptive sleep intervention perfectly fit for PD patients. The Niuiu headband, featuring our proprietary dry electrodes and AI/ML technology, operates in a dynamically adjusting, real-time closed-loop cycle involving EEG measurements and tACS neuromodulation interventions—highly individualized to each user. As we recently proved in a longitudinal clinical study on 25 PD patients in Germany, with a 3-4 day treatment protocol and with no need for cognitive feedback, Niuiu provides an ideal solution for PD patients that significantly improves their sleep and ability to cope with the disease and lasts several months after treatment. In this project phase, with the EIC support, our goal is to finalize the development of Niuiu for commercial use, continue its validation in clinical pilots, complete its MDR and FDA certification as a medical device and launch it in Europe followed by North America.

Keywords: tacs,long term potentiation,neuro plasticity,personalized neuro stimulation,theta,sleep staging,sleep cycle,neuromodulation,parkinson s disease,sleep disorders,insomnia,ndd
Metabolic adaptation in injuries of the peripheral nervous system (NERVADAPT)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing , nervous system  function and dysfunction , systems neuroscience  and modelling , biological basis of cognitive processes and of behaviour, neurological and mental disorders – In humans and all other organisms
Countries involved: Germany
Call: ERC CONSOLIDATOR GRANTS (ERC-2024-COG, 2024)
Start date: 2025-09-01
End date: 2030-08-31
Duration (months): 60.0
Total project cost (EUR): 1999995.0
EU funding (EUR): 1999995.0
Participants: 1
Project status: SIGNED

The peripheral nervous system constitutes a prime example of a tissue with a strong regenerative potential. Full recovery upon nerve trauma, however, is rare and usually fails in peripheral neuropathies - common, yet largely untreatable neurological disorders. Nerve repair strictly depends on the orchestration of both nerve de- and regeneration by peripheral nerve glial cells, which need to overcome a substantial metabolic challenge in injury. NervAdapt is based on the fundamental premise that Schwann cells, in the course of evolution, developed an exceptional metabolic adaptability to ensure repair. Capitalizing on acute nerve injury as a prototypic model system to explore conserved repair mechanisms, we aim to unveil glial metabolic adaptation to increased energetic demands and distinct substrate availabilities. A central goal of NervAdapt is to elucidate how glial homeostasis is integrated in a fine-tuned cellular network that extends to interactions with neighbouring tissue compartments. Employing elaborated genetic mouse models, 3D electron microscopy, and leading-edge spatial and single cell to organ level profiling approaches, NervAdapt will pioneer to generate a comprehensive multi-level framework of the nerve injury response. Chronic metabolic stressors, such as in diabetes and obesity, in turn, may lead to a constant glial overstimulation and compromise glial metabolic homeostasis. Metabolically induced neuropathies indeed underscore the specific vulnerability of the peripheral nervous system to a systemic metabolic burden. Within NervAdapt we follow the hypothesis that a persistently perturbed metabolic homeostasis causes molecular and cellular glial metabolic inflexibility, ultimately driving metabolic neuropathy. Together, NervAdapt seeks to identify key checkpoints of glial metabolic (mal-)adaptation under energy demand and metabolic load, revealing a new dimension of metabolic adjustment at the nerve organ level.

Keywords: schwann cell,myelin,neuropathy
Deeper Pulse: a software system for topology optimization in next-gen electric motor design (Deeper Pulse)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Deeper Pulse is on a mission to open a new era of digital innovation in electric motor (EM) design. We are fulfilling the world’s need for new, disruptive EM designs that will address the growing environmental pressure and the projected 3.5X growth of the share of EMs in the world’s energy consumption by 2050. To answer this challenge, Deeper Pulse developed a breakthrough software system for topology optimization in electric motors (EMs) that helps engineers create breakthrough EM designs. The system is based on over 10 years of research by Frédéric Messine's team at the Plasma and Energy Conversion Laboratory in Toulouse, France. Deeper Pulse extends topology optimization principles from mechanics to electromagnetics. Uniquely, our software creates a grid of “meshes” that represent the topology of an EM component (e.g. a stator or rotor), and then iteratively optimizes each mesh, sculpting the most appropriate shape and material composition (iron, copper, void) for the entire component. Our solution is faster than any other approach, allowing short iterations, and the creation of a manufacturable EM design in under 6 months. Our software is ~120X quicker at mesh processing than the closest AI-based competitor and is free from human engineering biases and preconceptions. As a result of our optimization, we reduce materials usage by 15-30%, increase motor torque by 20%, and reduce the Total Costs of Ownership by 40% on average for each electric motor. We target the automotive (€33.4B) and HVAC (€12.9B) electric motor market segments within the total EM market that is valued at €133B. We are seeking EIC support to extend the range of our software to such functions as demountability, manufacturing process optimization, and 3D simulation—the improvements that will allow us to become the dominant force in the next chapter of innovation in EM design.

Keywords: electric motors,electromagnetic topology optimization,iterative generative design,constraint based design
Clinical development of ONA-255, a First-in-Class ADC for Advanced Refractory HR+ HER2- Breast Cancer (ADC-ACHILLES)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Spain
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 38.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Ona Therapeutics (Ona) is developing ONA-255, a proprietary first in class antibody-drug conjugate (ADC) for the treatment of refractory HR+ HER2- advanced breast cancer (BC). HR+ HER2- is the most common BC subtype, affecting 1.6M people globally. While the 5-year survival rate for primary HR+ HER2- patients is 100%, advanced cases face a drastic decrease down to 34% in their 5-year survival rate. The current standard of care for HR+HER2- advanced BC is limited by a high relapse rate and adverse side effects. First-line therapies combining hormone therapy with a CDK4/6 inhibitor often lead to resistance, with all patients progressing within 4 years. Second-line treatment options using hormone therapy with targeted agents, such as mTOR and PI3K inhibitors or chemotherapy, are burdened with severe adverse effects and eventual relapse. Refractory patients, who develop resistance to both first and second-line therapies, have limited options . To address this urgent unmet medical need, Ona offers a groundbreaking, tailored first-in-class ADC therapy . ONA-255 was designed using real-world biopsies, from which Ona has identified and validated a target with dominant expression in advanced refractory HR+ HER2- BC and that is undetectable in healthy tissues. Consequently, ONA-255 is a highly effective, potent ADC, poised to overcome the high resistance and relapse rates associated with the current standard of care, and expected to have a superior safety profile. The ADC-ACHILLES project aims to acquire CTA approval and progress ONA-255 through a Phase I clinical trial to achieve clinical proof of concept. Completion of the Phase I trial will represent a significant value inflection point for Ona, which is expected to result in a strategic licensing deal for the completion of Phase II and Phase III clinical trials, and commercialization of ONA-255. Thereby, Ona will be able to become self-sufficient and invest in advancing its pipeline.

Keywords: advanced breast cancer,antibody drug conjugate,targeted therapy,patient biopsies,first in class
Optimization and Clinical Validation of EnteroCalm a Novel First-in-Class IBD (Inflammatory Bowel Disease) treatment. (EnteroCalm)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Denmark
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 36.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis (UC), pose significant challenges to patients and healthcare systems worldwide. Ulcerative Colitis (UC) is an incurable chronic inflammatory bowel disease that targets the large intestine. Based on the severity of the case, the symptoms can include weight loss to bloody diarrhoea and even potentially leading to colon cancer. Incidence rates for UC in Europe is 2.5-3 million people and this is increasing every year due to unhealthy lifestyles and increased stress levels. The current treatments, namely steroids, biologics and other small molecules cause side-effects in most cases and cost an average of €3.5-7k per year. EnteroTarget has created an innovative approach to address this problem providing an insulin-based rectal solution, and eventually a capsule that acts locally on the inflammation site and treats it with its anti-inflammatory properties. EnteroCalm offers two formulations: the EnteroCalm Enema, targeting the inflamed large intestine, and the EnteroCalm Shuttle, ingested orally for broad effectiveness. Both formulations utilize a novel drug delivery system designed for precise targeting and minimal systemic effects. EnteroCalm's mechanism of action involves local administration of insulin, targeting colonic epithelial cells to reduce inflammation without affecting immune cells. Clinical trials demonstrate the safety and efficacy of EnteroCalm, with minimal systemic uptake and no side effects observed. EnteroCalm presents a compelling value proposition, offering increased efficacy, reduced side effects, and cost-effectiveness compared to existing treatments. With its unique selling point of safety, affordability, and convenience, EnteroCalm emerges as a promising solution for UC patients worldwide, addressing unmet needs and enhancing patient outcomes and quality of life.

Keywords: well being,immunology
Next generation gene writing platform to cure genetic and oncological diseases (FiCAT)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Spain
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2024-12-01
End date: 2026-11-30
Duration (months): 24.0
Total project cost (EUR): 3566250.0
EU funding (EUR): 2496375.0
Participants: 1
Project status: SIGNED

Gene therapy offers a promising opportunity for treating the more than 10,000 human genetic diseases, as well as other disorders, such as cancer, by editing disease-causing genetic defects or engineering immune cells to target cancer cells. However, most genetic disorders remain untreatable, as gene therapy still holds an untapped potential due to significant limitations of current editing technologies, that are not efficient, precise and safe enough and thus, present limitations in scope and applicability. Integra Therapeutics, a spin-off of the Pompeu Fabra University (UPF) has developed an advanced genome writing platform that overcomes the limitations of current gene editing technologies. Our proprietary gene writing technology platform- FiCAT combines the precision of RNA-guided nucleases with the effectiveness of programmable transposases to insert large pieces of DNA in a safe, precise and stable way. FiCAT has the capacity to integrate virtually any gene into the genome with unprecedented efficiency, precision and safety. FICAT has already been validated in several ex vivo and in vivo models. With FiCAT, we will unlock the potential of gene writing to cure genetic diseases and bring life-changing therapies to patients suffering from high unmet need genetic and neoplastic diseases.

Keywords: transposases,nucleases,large therapeutic payloads,gene writing tools,genetic diseases,pfic2,gene editing,crispr
Building the world’s largest digital hospital for neurological challenges (VR4NEURO)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Finland
Call: EIC Accelerator Open (HORIZON-EIC-2022-ACCELERATOR-01, 2022)
Start date: 2022-11-01
End date: 2025-03-31
Duration (months): 29.0
Total project cost (EUR): 3565875.0
EU funding (EUR): 2496112.0
Participants: 1
Project status: CLOSED

Peili Vision was founded in 2015 based on a vision to help people rehabilitate after traumatic health events, such as stroke. By combining VR technology, artificial intelligence, gamification and the latest science in neurorehabilitation, our mission is to empower every rehabilitee to train in the most effective way and as frequently as possible from the comfort of their own home. Our evidence-based novel rehabilitation methods enable feedback and progress tracking remotely. Remote approach addresses the key bottleneck in this field: lack of rehabilitation professionals, which is why currently the cost of rehabilitation services is very high while the availability is very limited, especially in rural and remote areas. Our first product is designed for speech therapy. In the next phase, with the support of the EIC funding, we will expand our product-service offering to cover the entire patient care path, from remote diagnostics to AI-designed therapy programs and medication evaluation.

Keywords: remote rehabilitation therapy,neurorehabilitation,occupational therapy,neurophysiology,neuropsychology,clinical evaluation,neurological disorder diagnosis,therapeutic tools,gamification,virtual reality,speech and language therapy
makinG aUgmedit lumI stanDArd in NeurosurgiCal surgEry in 3D: GUIDANCE 3D (makinG aUgmedit lumI stanDArd in NeurosurgiCal surgEry in 3D: GUIDANCE 3D)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Netherlands
Call: EIC Accelerator Open (HORIZON-EIC-2022-ACCELERATOR-01, 2022)
Start date: 2023-01-01
End date: 2025-05-31
Duration (months): 29.0
Total project cost (EUR): 2452491.25
EU funding (EUR): 1716743.0
Participants: 1
Project status: CLOSED

Augmedit develops and brings to market Augmented Reality SaaS applications for surgeons. AR gives the possibility of viewing holographic images in 360◦. It is our mission to transform the complete 2D clinical practice into an intuitive 3D world as the first company in the world. Until now, AR applications are unavailable in (neuro)surgical setting due to lacking accuracy and automatization of workflows. Augmedit’s Lumi Elite solves this problem. We make surgery safer by guiding the medical specialist with an intuitive AR application that automatically generates holograms from medical imaging and projects them with a surgical plan on the patient. This holographic experience improves the insight of surgeons and drives massive cost savings for medical institutions. Crucially, Lumi Elite will improve the preoperative and operative care of the patients: 1 hologram is worth more than a 1000 scans.

Keywords: artificial intelligence,engineering and technology,digital services,computational engineering,clinical medicine